-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Recent Approvals of CAR T Therapy for Hematologic Malignancies

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
Hematology Disease Topics & Pathways:
Drug development, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Gene Therapy, Treatment Considerations, Biological therapies, Immunotherapy
Monday, December 9, 2024, 10:30 AM-12:00 PM

'Lola Fashoyin-Aje, MD, MPH

Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD

Disclosures: No relevant conflicts of interest to declare.

See more of: ASH-FDA Joint Symposium I: Accelerating Drug Development for Hematologic Malignancies
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>